Summary:
Hospital groups criticize proposed 340B changes, warning of increased burdens and uncertainty as program oversight may shift from HRSA to CMS.
Drug companies and hospitals are clashing over a new rebate model for discounted medications, which could change how hospitals pay for drugs and receive savings. A government pilot program is testing this approach with a small selection of drugs, sparking debate about costs, cash flow, and administrative hurdles. Curious about how this could impact hospitals and patients? Read on for the key details behind the controversy.
Source: 340B Rebate Models Arrive in the Form of a New Pilot Program, Nick Hut, HFMA, August 4, 2025; https://www.hfma.org/accounting-and-financial-reporting/340b-rebate-models-arrive-in-the-form-of-a-new-pilot-program/
Topics
Economics
Healthcare Process
Action Orientation
Related
Research: As Careers Get Longer, Midcareer Work Needs to ChangeThe Power of Strategic CenteringReducing Clinical Variation Through Interdisciplinary Leadership: A Field Report from a Large Academic Medical CenterRecommended Reading
Problem Solving
The Power of Strategic Centering
Quality and Risk
Reducing Clinical Variation Through Interdisciplinary Leadership: A Field Report from a Large Academic Medical Center
Quality and Risk
3 Medical Routines That Older People May Not Need